Drug Profile

Diarylquinoline - TB Alliance

Alternative Names: TBAJ-587

Latest Information Update: 30 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator European Regimen Accelerator for Tuberculosis; Global Alliance for TB Drug Development
Class Antituberculars; Diarylquinolines; Ethers; Fluorinated hydrocarbons; Pyridines; Small molecules
Mechanism of Action Adenosine triphosphatase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Sep 2026 TASK Applied Science plans a phase II SYNERGY trial for Pulmonary tuberculosis (Combination therapy) in South Africa (PO, Tablet) in September 2026 (NCT07773610)
20 Mar 2025 Phase-I development is ongoing in Tuberculosis in Netherlands (PO, Suspension) (AB Alliance pipeline, March 2025)
28 Nov 2024 No recent reports of development identified for phase-I development in Tuberculosis in Netherlands (PO, Suspension)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com